Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational ...

One of them had to do with Citadel's position in the pharmaceutical giant Eli Lilly (NYSE: LLY). Ken Griffin and his team ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But ...

Discover 25 top investment-grade stocks to buy! See strategies to capitalize on market volatility and build a portfolio to ...

European stocks look like newly good investments amid Trump's tariff war and US economic unpredictabilities. European defense stocks are particularly appealing.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

The major indexes suffered another week of sharp losses as Trump tariffs ramped up, shrugging off tame inflation.

The story of Republican tax policy in the Trump era is the contest between pro-growth ideas and anti-growth income redistribution. An example of both was on display in President Trump’s recent speech ...

Eli Lilly just scored a major win with its Phase 3 BRAVE-AA-PEDS study. The trial confirmed baricitinib's effectiveness in ...